[News Brief] Hyphens Pharma Out-licenses Cerapro® MED to European Markets
Hyphens Pharma Pte. Ltd. has entered into an out-licensing agreement for its skin barrier cream, Cerapro® MED Skin Barrier Cream,…
Hyphens Pharma Pte. Ltd. has entered into an out-licensing agreement for its skin barrier cream, Cerapro® MED Skin Barrier Cream,…
Johnson & Johnson announced a significant milestone with its TECNIS ODYSSEY IOL being implanted in 100,000 eyes in the U.S.…
Gene Solutions has completed the K-DETEK trial, making SPOT-MAS the first multi-cancer early detection (MCED) blood test in Asia to…
Gene Solutions, in partnership with Gene Health, has launched SPOT-MAS in Taiwan, an AI-driven multi-cancer early detection (MCED) solution designed…
Gene Solutions showcased advancements in Molecular Residual Disease (MRD) and AI-powered multi-omics technologies at the Singapore Society of Oncology Annual…
On 22 October 2025, Raffles Medical Group (RMG) and Gene Solutions signed a Memorandum of Understanding (MOU) to streamline patient…
Gene Solutions concluded the European Society for Medical Oncology (ESMO) Asia Congress 2025 in Singapore (5–7 December) with a focus…
Lucence and the Diagnostics Development Hub (DxD Hub), a national platform hosted by Singapore’s Agency for Science, Technology and Research…
Lucence has announced that its LiquidHALLMARK® ctDNA/ctRNA liquid biopsy test has received Medicare coverage approval through the Molecular Diagnostic Services…
Mayo Clinic Laboratories and Lucence announced a strategic collaboration on 10 January 2025 to increase global access to liquid biopsy…